Diagnostic Approach to Angioedema

Initial Assessment

The American Academy of Allergy, Asthma, and Immunology recommends determining if angioedema is accompanied by urticaria (wheals) or occurs alone to distinguish between histaminergic and non-histaminergic forms 1, 2
A detailed medication history, particularly focusing on ACE inhibitors, ARBs, NSAIDs, and other potential triggers, is essential for identifying potential causes of angioedema 3, 4
Assessing for family history of angioedema may suggest hereditary forms, with documentation of duration of individual swelling episodes (>24 hours suggesting non-histaminergic forms) 1, 2

Laboratory Testing

The American College of Allergy, Asthma, and Immunology suggests that serum C4 level is an excellent initial screening test for C1 inhibitor deficiency, with low levels present in 95% of patients with C1INH deficiency between attacks and nearly 100% during attacks 3, 5
C1 inhibitor (C1-INH) antigenic and functional levels are essential for diagnosing and distinguishing between types of hereditary angioedema 3, 4
For suspected acquired C1 inhibitor deficiency, C1q level and C1-INH antibodies can help identify autoimmune-mediated acquired angioedema 3, 4, 5

Special Considerations

The American Heart Association notes that no specific diagnostic test exists for ACE inhibitor-induced angioedema, with diagnosis confirmed by resolution of symptoms after discontinuation of the medication (may take up to 6 weeks) 3, 4
Consider higher risk in African Americans, smokers, older patients, and females for ACE inhibitor-induced angioedema 4
For suspected inflammatory/autoinflammatory conditions, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can assess for underlying inflammatory conditions, and paraprotein screening can rule out associated conditions 2

Disease Monitoring Tools

The American Academy of Allergy, Asthma, and Immunology recommends using the 7-Day Urticaria Activity Score for patients with chronic spontaneous urticaria with wheals, and the Angioedema Activity Score for patients with angioedema with or without wheals 1, 6, 7, 8
The Urticaria Control Test (UCT) and Angioedema Control Test (AECT) can assess disease control in patients with wheals with/without angioedema 7, 8

Diagnostic Approach to Angioedema

Initial Screening Tests

A normal C4 level during an attack strongly suggests hereditary angioedema (HAE) is unlikely, according to the American Academy of Allergy, Asthma, and Immunology 9
The American College of Allergy, Asthma, and Immunology recommends C1 inhibitor (C1-INH) testing, including C1-INH antigenic level and C1-INH functional level, to help distinguish between HAE type I and type II 9

Genetic Testing and Additional Tests

Genetic testing for mutations in factor XII (FXII), angiopoietin-1 (ANGPT1), plasminogen (PLG), kininogen (KNG1), myoferlin (MYOF), and heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6) is recommended for suspected hereditary angioedema with normal C1-INH (HAE-nl-C1-INH), as suggested by the American Academy of Allergy, Asthma, and Immunology 10
The American College of Allergy, Asthma, and Immunology recommends C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) tests for suspected inflammatory/autoinflammatory conditions, and paraprotein screening 10

Laboratory Patterns in Different Types of Angioedema

HAE Type I is characterized by low C4, low C1-INH antigen, low C1-INH function, and normal C1q, according to the American Academy of Allergy, Asthma, and Immunology 9
HAE Type II is characterized by low C4, normal/elevated C1-INH antigen, low C1-INH function, and normal C1q, as recommended by the American College of Allergy, Asthma, and Immunology 9

Laboratory Testing for Angioedema

Distinguishing Between Types of Angioedema

The American Academy of Allergy, Asthma, and Immunology recommends that a low C1q level is critical to differentiate acquired C1 inhibitor deficiency from hereditary forms, with acquired C1 inhibitor deficiency typically having low C4, low C1-INH antigen/function, and low C1q 11
The pattern of results, including low C4, low C1-INH antigen, low C1-INH function, and normal C1q, is consistent with HAE Type I, which accounts for 85% of cases, according to the Journal of Allergy and Clinical Immunology 11
Acquired C1 inhibitor deficiency can be distinguished from hereditary forms by a low C1q level, which should be specifically stipulated when ordering the test, as recommended by the Journal of Allergy and Clinical Immunology 11

Diagnostic Approach to Angioedema

Initial Evaluation

For patients presenting with angioedema and hives, the American Academy of Allergy, Asthma, and Immunology recommends obtaining a differential blood count, C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), total IgE level, and IgG-anti-thyroid peroxidase (anti-TPO) antibodies as the basic laboratory panel, which helps identify underlying inflammatory or infectious processes, assesses for inflammatory conditions, and distinguishes between different forms of urticaria 12
The presence of elevated total IgE levels suggests autoallergic chronic spontaneous urticaria (CSU), while elevated IgG-anti-TPO levels indicate autoimmune CSU, according to the American Academy of Allergy, Asthma, and Immunology 12
A high ratio of IgG-anti-TPO to total IgE is a surrogate marker for autoimmune CSU, as stated by the American Academy of Allergy, Asthma, and Immunology 12

Diagnostic Testing for Hereditary Angioedema

When angioedema occurs without hives, the European Academy of Allergy and Clinical Immunology recommends immediately measuring C4 level, C1 inhibitor (C1-INH) antigen, and C1-INH functional activity to screen for hereditary or acquired C1 inhibitor deficiency 13
If acquired C1-INH deficiency is suspected, the European Academy of Allergy and Clinical Immunology suggests measuring C1q level and anti-C1INH antibodies, which helps differentiate acquired from hereditary forms 13

Genetic Testing

For patients with recurrent angioedema without hives who have normal C1-INH levels but fail to respond to antihistamines and omalizumab, the European Academy of Allergy and Clinical Immunology recommends performing targeted gene sequencing for known HAE pathogenic variants, including testing for mutations in Carboxypeptidase N1 (CPN1) and DAB2 interacting protein (DAB2IP) 14

Clinical Distinctions

The presence or absence of urticaria (hives) is crucial in determining the mechanism and appropriate testing strategy, with angioedema WITH hives suggesting mast cell-mediated mechanisms and angioedema WITHOUT hives suggesting bradykinin-mediated mechanisms or hereditary forms, according to the European Academy of Allergy and Clinical Immunology 14
Approximately 10% of chronic urticaria patients present with angioedema alone without visible wheals, complicating the diagnostic picture, as noted by the European Academy of Allergy and Clinical Immunology 14

Medication-Induced Angioedema

Obtaining a detailed medication history is essential, particularly for ACE inhibitors, ARBs, NSAIDs, neprilysin inhibitors, and DPP-IV inhibitors, which are common causes of non-histaminergic angioedema, according to the European Academy of Allergy and Clinical Immunology 13

Differential Diagnoses of Angioedema Without Urticaria

Primary Differential Categories

The American Academy of Allergy, Asthma, and Immunology recommends considering bradykinin-mediated causes rather than histamine-mediated mechanisms when a patient presents with angioedema without urticaria, as this fundamentally changes both diagnosis and treatment 15, 16
The absence of urticaria narrows the differential significantly and mandates evaluation for C1 inhibitor deficiency, as these patients will not respond to standard antihistamine therapy 15, 16

Drug-Induced Angioedema

ACE inhibitor-induced angioedema is the most common cause, affecting 0.1-0.7% of patients taking these medications and accounting for approximately half of acute angioedema hospital admissions 15, 16
ACE inhibitor-induced angioedema can occur within the first month of therapy but may develop even after many years of continuous use 15, 16
ARB-associated angioedema occurs less commonly but remains in the differential, particularly in patients switched from ACE inhibitors 15, 16

Common Pitfalls to Avoid

The American College of Allergy, Asthma, and Immunology advises against assuming ACE inhibitor-induced angioedema only occurs early in treatment, as it can develop after many years of stable therapy 15, 16
Do not expect rapid resolution after ACE inhibitor discontinuation, as the propensity to swell can continue for at least 6 weeks after stopping the medication 15
The American Academy of Allergy, Asthma, and Immunology recommends against treating bradykinin-mediated angioedema with epinephrine, antihistamines, or corticosteroids, as these are ineffective and delay appropriate therapy 15, 16
African Americans, smokers, older patients, and females have a higher risk for ACE inhibitor-induced angioedema 15

Allergy Testing for Angioedema with Unknown Trigger

Initial Approach

For angioedema with an unknown trigger, the initial approach should prioritize determining whether urticaria is present, and if angioedema occurs with urticaria, order skin prick testing and allergen-specific IgE testing, according to the American Academy of Allergy, Asthma, and Immunology 17, 18
If angioedema occurs without urticaria, immediately order C4 level, C1 inhibitor antigen, and C1 inhibitor functional activity instead of allergy tests, as recommended by the American Academy of Allergy, Asthma, and Immunology 17, 18

Diagnostic Testing

Skin prick testing (SPT) is recommended to identify potential food or environmental allergens in patients with angioedema and urticaria, as suggested by the American College of Allergy, Asthma, and Immunology 17, 18, 19
Allergen-specific serum IgE testing is recommended as an alternative or adjunct to skin testing in patients with angioedema and urticaria, according to the American Academy of Allergy, Asthma, and Immunology 19
In vitro testing and challenges are recommended when indicated, based on clinical suspicion, as suggested by the American College of Allergy, Asthma, and Immunology 17, 18

Complement Testing

C4 level is an excellent screening test for C1-INH deficiency, with low levels found in 95% of cases between attacks, as reported by the European Academy of Allergy and Clinical Immunology 17, 18
C1 inhibitor (C1-INH) antigenic level and C1-INH functional activity are recommended for patients with angioedema without urticaria, as suggested by the American Academy of Allergy, Asthma, and Immunology 17, 18

Diagnostic Approach for Angioedema

Initial Evaluation and Testing

For any patient presenting with angioedema, immediately order C4 level, C1 inhibitor (C1-INH) antigen, and C1-INH functional activity to screen for hereditary or acquired C1 inhibitor deficiency, as recommended by the American Academy of Allergy, Asthma, and Immunology 20, 21
Obtain photographic, laryngoscopic, or imaging evidence to differentiate true angioedema from factitious angioedema or non-angioedematous symptoms, according to the European Academy of Allergy and Clinical Immunology 20, 21
Review all medications, particularly ACE inhibitors, ARBs, NSAIDs, neprilysin inhibitors, and DPP-IV inhibitors, which are common culprits, as noted by the American College of Allergy, Asthma, and Immunology 20, 21
Obtain detailed family history for recurrent angioedema or known HAE diagnoses, as suggested by the World Allergy Organization 20, 21

Advanced Diagnostic Testing

If acquired C1-INH deficiency is suspected, order C1q level and anti-C1INH antibodies to differentiate from hereditary forms, as recommended by the American Academy of Allergy, Asthma, and Immunology 20, 21
For patients unresponsive to mast cell therapy and with strong clinical suspicion, consider genetic testing with targeted gene sequencing for known HAE pathogenic variants, according to the European Academy of Allergy and Clinical Immunology 20, 21

Imaging and Laboratory Studies

For predominant gastrointestinal attacks, consider abdominal CT or ultrasound during an attack to evaluate for bowel wall edema and intraperitoneal fluid, which confirms true abdominal angioedema, as noted by the American Gastroenterological Association 20, 21
HAE with normal C1-INH requires genetic testing, as stated by the World Allergy Organization 20, 21

Critical Considerations

Do NOT assume normal C1-INH levels exclude hereditary angioedema—HAE with normal C1-INH exists and requires genetic testing, as warned by the American College of Allergy, Asthma, and Immunology 20, 21

Investigation for C1 Inhibitor Deficiency

Diagnostic Approach

The British Journal of Dermatology guidelines recommend C1 inhibitor testing only when angioedema occurs without weals/urticaria, as the presence of weals suggests a mast cell-mediated mechanism rather than bradykinin-mediated angioedema 22, 23
The initial screening test for C1 inhibitor deficiency should be the serum C4 level, which has high sensitivity and is low in 95% of patients between attacks and nearly 100% during active attacks, according to the Journal of Allergy and Clinical Immunology 22, 23, 24
A normal C4 level during an attack essentially excludes C1 inhibitor deficiency, as stated by the Journal of Allergy and Clinical Immunology 24

Interpretation of Test Results

Type I Hereditary Angioedema is characterized by low C4, low C1-INH antigen, low C1-INH function, and normal C1q, according to the Journal of Allergy and Clinical Immunology 24
Type II Hereditary Angioedema is characterized by low C4, normal/elevated C1-INH antigen, low C1-INH function, and normal C1q, as stated by the Journal of Allergy and Clinical Immunology 24
Acquired C1 Inhibitor Deficiency is characterized by low C4, low C1-INH antigen, low C1-INH function, and low C1q, according to the British Journal of Dermatology and the Journal of Allergy and Clinical Immunology 22, 24

Special Considerations

HAE with normal C1 inhibitor (HAE-nC1INH) requires genetic testing for known pathogenic variants and diagnosis of exclusion, as stated by Clinical Reviews in Allergy and Immunology 25, 26
The American Academy of Allergy, Asthma, and Immunology is not mentioned in this article, however the British Journal of Dermatology guidelines recommend that C1 inhibitor testing should not be ordered in patients with urticaria/weals present 22, 23
The strength of evidence for these facts is not explicitly stated, but they are based on guidelines and recommendations from reputable medical journals 22, 23, 24, 25, 26

Diagnostic and Work‑up Recommendations for Facial Angioedema

1. Evaluation for Acquired C1‑Inhibitor Deficiency

In adults presenting with facial angioedema without wheals and no family history, order a paraprotein screen to exclude underlying lymphoproliferative disorders that can cause acquired C1‑inhibitor deficiency. 27

2. Genetic Testing for Hereditary Angioedema with Normal C1‑Inhibitor Levels

When clinical suspicion for hereditary angioedema remains high despite normal C1‑inhibitor antigen and function, perform targeted gene sequencing for known pathogenic variants, most commonly Factor XII (FXII) mutations. This testing is especially relevant for patients who do not respond to antihistamines or omalizumab. 28

3. Inflammatory/Autoinflammatory Work‑up (when systemic symptoms accompany angioedema)

Obtain C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to evaluate for concurrent inflammatory conditions. 27
Conduct a paraprotein screen in adults to rule out Schnitzler syndrome as a cause of recurrent angioedema with systemic features. 27
If individual wheals persist longer than 24 hours, consider a skin biopsy to assess for urticarial vasculitis. 27

4. Medication History Documentation

Record use of angiotensin‑II receptor blockers (ARBs) as they are implicated in drug‑induced angioedema. 27
Document exposure to dipeptidyl‑peptidase IV inhibitors (gliptins), which have been associated with angioedema episodes. 27
Note use of neprilysin inhibitors, another medication class linked to angioedema risk. 27